MYCBP2

Across TCGA pan-cancer cohorts, MYCBP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYCBP2 data layer compared with 18 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MYCBP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYCBP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where MYCBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.797	0.374	<.001	27	view →
HNSC	OS	Tertile	III,IV	1.000	0.277	.013	13	view →
PDAC	DFS	Tertile	IV	0.752	0.205	.024	6	view →
LSCC	DFS	Median	All	0.907	0.464	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYCBP2–LUAD (DFS)

Open the LUAD breakdown →